SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$2.78 USD
+0.08 (2.79%)
Updated Jul 31, 2024 12:22 PM ET
After-Market: $2.84 +0.06 (2.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
SABS 2.78 +0.08(2.79%)
Will SABS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SABS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SABS
Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
SABS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Illumina (ILMN) Beats Q1 Earnings and Revenue Estimates
SAB Biotherapeutics, Inc. (SABS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for SABS
SAB Biotherapeutics Announces Key Executive Appointment
SAB BIO Appoints Lucy To as Chief Financial Officer
SAB Biotherapeutics names Lucy To as CFO
SAB Biotherapeutics appoints Lucy To as Chief Financial Officer
SAB Biotherapeutics management to meet with Oppenheimer